US Market Preview | QTTB Surges 110.5%; BOJ Governor Hints at December Rate Hike, Futures Drop; Trump Picked New Fed Chair Candidate
Sahm Platform 01/12 13:48
BARDA Selects Edesa Biotech's Paridiprubart For U.S. Funded Platform Trial In General ARDS
EDESA BIOTECH INC +2.74%
EDESA BIOTECH INC EDSA | 0.00 |
- This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes.
- This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.
- Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates.
TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced today that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study.
Recommend
Janux dives as gaps in prostate cancer study data worry investors
Reuters 02/12 15:45Peering Into Starbucks Corp's Recent Short Interest
Benzinga News 02/12 16:00Amazon and Adobe Deepen AI Collaboration to Advance Creativity and Marketing
Reuters 02/12 16:06Dine Brands Global Inc. to Participate in Major Investor Conferences
Reuters 02/12 17:00Is GE Vernova’s Growth Priced In After the 74% Rally and Spin-Off News?
Simply Wall St 02/12 18:20Figma (FIG): Exploring Valuation After Recent Share Price Volatility
Simply Wall St 02/12 19:22Brand Engagement Network Announces 1-for-10 Reverse Stock Split
Reuters 02/12 20:22
